- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00738374
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
torstai 6. heinäkuuta 2017 päivittänyt: Hoffmann-La Roche
A Study of Chlorambucil Plus MabThera as Induction Therapy Followed in Responders by Maintenance Therapy Versus Observation on Response Rate in Patients >=60 Years With Previously Untreated Chronic Lymphocytic Leukemia
This single arm study will assess the efficacy and safety of MabThera + chlorambucil as induction therapy, followed in responders by maintenance therapy or observation in elderly patients with previously untreated chronic lymphocytic leukemia.
During the induction phase patients will receive 2 x 4 weekly courses of chlorambucil followed by 8 x 4 weekly courses of chlorambucil + MabThera.
Subsequently, responders will be randomized to receive 12 doses of MabThera given every 8 weeks, or no further treatment.
The anticipated time on study treatment is 2+ years, and the target sample size is <100 individuals.
Tutkimuksen yleiskatsaus
Tila
Valmis
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
97
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Calabria
-
Catanzaro, Calabria, Italia, 88100
- Az. Osp. Pugliese; Dh Oncologico
-
Cosenza, Calabria, Italia, 87100
- P.O. Annunziata; U.O. Ematologia
-
Reggio Calabria, Calabria, Italia, 89100
- Ospedale Riuniti; Divisione Di Ematologia
-
-
Campania
-
Napoli, Campania, Italia, 80131
- Ospedale Cardarelli; Divisione Di Ematologia
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italia, 40138
- A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
-
Ferrara, Emilia-Romagna, Italia, 44100
- Arcispedale S. Anna; Sezione Di Ematologia
-
-
Lazio
-
Roma, Lazio, Italia, 00161
- Universita' Degli Studi La Sapienza-Ist.Di Ematologia;Dip. Biotecnologie Cel CELLULARI ED EMATOLOGIA
-
Roma, Lazio, Italia, 00144
- Ospedale S. Eugenio; Divisione Di Ematologia
-
-
Liguria
-
Genova, Liguria, Italia, 16132
- Uni Degli Studi Di Genova; 1A Divisione Di Ematologia
-
-
Lombardia
-
Milano, Lombardia, Italia, 20122
- Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora
-
Milano, Lombardia, Italia, 20162
- Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
-
-
Piemonte
-
Torino, Piemonte, Italia, 10126
- A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia
-
Torino, Piemonte, Italia, 10126
- Ospedale Molinette - Universita' Di Torino; Cliniche Universitarie Ematologia I
-
-
Puglia
-
Bari, Puglia, Italia, 70124
- Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica
-
-
Sicilia
-
Messina, Sicilia, Italia, 98165
- Az. Osp. Papardo; Struttura Complessa Di Ematologia
-
Via S. Sofia 78, Sicilia, Italia, 95123
- Ospedale Ferrarotto; Divisione Di Ematologia
-
-
Toscana
-
Firenze, Toscana, Italia, 50135
- Az. Osp. Di Careggi; Divisione Di Ematologia
-
Siena, Toscana, Italia, 53100
- A.O. Universitaria Senese; Ematologia
-
-
Veneto
-
Padova, Veneto, Italia, 35128
- Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia
-
Verona, Veneto, Italia, 37134
- Policlinico G. B. Rossi; Divisione Di Ematologia
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
60 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- adult patients, >=60 years of age;
- CD20+ chronic lymphocytic leukemia (CLL);
- no previous treatment for CLL;
- ECOG performance status 0-1.
Exclusion Criteria:
- co-morbid conditions requiring long term use of systemic corticosteroids during study treatment;
- history of severe cardiac disease;
- transformation to aggressive B-cell malignancy.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: 1
|
375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
8mg/m2 po on days 1-7 of courses 1-8
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percentage of Participants With Documented CR, CRi, or PR at the End of Induction Treatment
Aikaikkuna: Month 10
|
CR defined as: 1) laboratory CR: peripheral blood lymphocytes (PBL) less than (<) 4000/microliter (μL), neutrophils (PMN) greater than (>) 1500/μL, platelets >100,000/μL, and hemoglobin (Hb) >11 grams per deciliter (g/dL); 2) clinical CR: lymph nodes (LN) <1.5 centimeter (cm), and no constitutional symptoms, hepatomegaly (HM) or splenomegaly (SM); 3) instrumental CR: LN <1.5 cm and no HM/SM, and 4) bone marrow (BM) CR: normocellular aspirate/biopsy for participant age <30 percent (%) lymphocytes, and no B cell lymphoid nodules.
CRi was defined as CR with anemia, thrombocytopenia, or neutropenia not related to chronic lymphocytic leukemia (CLL), with no clonal infiltrate in aspirate or biopsy.
PR defined as: a 50% decrease in PBL, a 50% decrease in LN size, no increase in LN size, no new enlarged LN, a 50% reduction from baseline (BL) in the HM/SM, and 1 of the following: PMN >1500/μL, platelets >100,000/μL or >50% improvement from BL, and Hb >11.0 g/dL or >50% improvement from BL.
|
Month 10
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percentage of Participants With Documented CR, CRi, or PR at the End of Study
Aikaikkuna: Month 35
|
CR defined as: 1) laboratory CR: PBL <4000/μL, PMN > 1500/μL, platelets > 100,000/μL, and Hb > 11 g/dL; 2) clinical CR: LN < 1.5 cm, and no constitutional symptoms, HM or SM; 3) instrumental CR: LN < 1.5 cm and no HM/SM, and 4) bone marrow CR: normocellular aspirate/biopsy for participant age < 30% lymphocytes, and no B cell lymphoid nodules.
CRi was defined as CR with anemia, thrombocytopenia, or neutropenia not related to CLL, with no clonal infiltrate in aspirate or biopsy.
PR defined as: a 50% decrease in PBL, a 50% decrease in LN size, no increase in LN size, no new enlarged LN, a 50% reduction from BL in the HM/SM, and 1 of the following: PMN > 1500/μL, platelets > 100,000/μL or > 50% improvement from BL, and Hb >11.0 g/dL or > 50% improvement from BL.
|
Month 35
|
Percentage of Participants With CR, CRi, PR, Stable Disease (SD), Progressive Disease (PD), Relapse, or Nodular PR at the End of Induction Treatment
Aikaikkuna: Month 10
|
CR, CRi, and PR as previously defined.
PD was defined by 1 of the following: 1) lymphadenopathy: any new lesion, HM/SM, or other organ infiltrates, or a greater than or equal to (≥) 50% increase in greatest diameter of any previously noted lesion; 2) a ≥ 50% increase in previously noted HM/SM, or new appearance of HM/SM; 3) a ≥ 50% increase in blood lymphocyte count with at least 5000 B lymphocytes/μL; 4) transformation to a more aggressive histology, e.g., Richter's syndrome; or 5) occurrence of cytopenia attributable to CLL.
SD was defined by the absence of necessary criteria to achieve CR or PR, but no advancement to PD. Relapse was defined by a previously noted CR or PR with advancement to PD after a period of ≥ 6 months.
Nodular PR was defined by the presence of residual lymphoid nodules.
|
Month 10
|
Percentage of Participants With CR, PR, SD, PD, Relapse, or Nodular PR at the End of Study
Aikaikkuna: Month 35
|
CR, and PR as previously defined.
PD was defined by 1 of the following: 1) lymphadenopathy: any new lesion, HM/SM, or other organ infiltrates, or a ≥ 50% increase in greatest diameter of any previously noted lesion; 2) a ≥50% increase in previously noted HM/SM, or new appearance of HM/SM; 3) a ≥50% increase in blood lymphocyte count with at least 5000 B lymphocytes/μL; 4) transformation to a more aggressive histology, e.g., Richter's syndrome; or 5) occurrence of cytopenia attributable to CLL.
SD was defined by the absence of necessary criteria to achieve CR or PR, but no advancement to PD. Relapse was defined by a previously noted CR or PR with advancement to PD after a period of ≥6 months.
Nodular PR was defined by the presence of residual lymphoid nodules.
|
Month 35
|
Number of Participants With Immunophenotypic CR - BM, Immunophenotypic CR - Peripheral Blood (PB), Molecular CR - BM, or Molecular CR - PB at the End of Induction Treatment
Aikaikkuna: Month 10
|
Immunophenotypic CR was defined as the absence of minimal residual disease (MRD) evaluated in participants with CR by 4-color flow cytometry of PB and BM B cells to confirm that tissue was comprised of non-CLL cells.
Molecular CR was defined as the absence of MRD evaluated in participants with CR by quantitative polymerase chain reaction (PCR) in PB and BM B cells to confirm that tissue was comprised of non-CLL cells.
|
Month 10
|
Percentage of Participants With CR, CRi, PR, SD, PD, or Relapse at the End of Study
Aikaikkuna: Month 35
|
CR, CRi, PR, SD, PD, relapse, and nodular PR as previously defined.
|
Month 35
|
Percentage of Participants With Immunophenotypic CR - BM or Immunophenotypic CR - PB at the End of Study
Aikaikkuna: Month 35
|
Immunophenotypic CR was defined as the absence of MRD evaluated in participants who achieved CR by 4-color flow cytometry of PB and BM B cells to confirm that tissue was comprised of non-CLL cells.
|
Month 35
|
Percentage of Participants With Molecular CR - BM or Molecular CR - PB at the End of Study
Aikaikkuna: Month 35
|
Molecular CR was defined as the absence of MRD evaluated in participants who achieved CR by quantitative PCR in PB and BM B cells to confirm that tissue was comprised of non-CLL cells.
|
Month 35
|
Number of Participants With Disease Progression, Relapse, Death, Withdrawal Because of an Adverse Event (AE), or New CLL Treatment
Aikaikkuna: Screening, Days 1 and 15 of Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Event-free Survival (EFS) was defined as the time from the first dose of study treatment to the date of first documentation of disease progression, relapse for participants with previous CR, death due to any cause, withdrawal due to AE, or beginning new CLL treatment.
CR and PD as previously defined.
Participants were censored at the time of data cut-off to the most recent date of disease assessment.
Participants without a post-BL disease assessment were censored at the time of first dose of study treatment.
|
Screening, Days 1 and 15 of Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
EFS
Aikaikkuna: Screening, Days 1 and 15 of Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
The median time, in days, from the the date of first dose of study treatment to the date of first documentation of disease progression, relapse for participants with CR, death due to any cause, withdrawal due to AE, or new CLL treatment.
CR and PD as previously defined.
Participants were censored at the time of data cut-off to the most recent date of disease assessment.
Participants without a post-BL disease assessment were censored at the time of first dose if study treatment.
The 95% CI was determined using Kaplan-Meier methodology.
|
Screening, Days 1 and 15 of Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Number of Participants With Disease Progression or Death
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Progression-free survival (PFS) was defined as the time from the first dose of study treatment to the first documentation of disease progression or death.
PD as previously defined.
Participants who were withdrawn from the study without documented disease progression were censored at the date of the last tumor assessment when the participant was known to be progression-free.
Participants without a post-BL tumor assessment, but known to be alive, were censored at the time of the first dose of study treatment.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
PFS
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
The median time, in days, from the date of the first dose of study treatment to the date of first documentation of disease progression or death.
CR and PD as previously defined.
Participants who were withdrawn from the study without documented disease progression were censored at the date of the last tumor assessment when the participant was known to be progression-free.
Participants without a post-BL tumor assessment, but known to be alive, were censored at the time of the first dose of study treatment.
The 95% CI was determined using Kaplan-Meier methodology.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Number of Participants With New CLL Treatment or Death
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Time to new CLL treatment (TTNT) was defined as the time from the first dose of study treatment to the date of new CLL treatment received or the date of death from any cause.
Participants who did not receive new CLL treatment and were alive at the time of the analysis were censored at the date of the last follow-up assessment.
Participants without a follow-up assessment were censored at the day of last dose of study treatment.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Time to Next Treatment (TTNT)
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
The mean time, in days, from the date of the first dose of study treatment to the date of new CLL treatment or the date of death from any cause.
Participants who did not receive new CLL treatment and were alive at the time of the analysis were censored at the date of the last follow-up assessment.
Participants without a follow-up assessment were censored at the day of last dose of study treatment.
Mean survival time and it's standard error (SE) were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Number of Participants Who Died
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Overall Survival (OS) was defined as the time from the date of the first dose of study treatment to the date of death due to any cause.
Participants were censored at the date of the last follow-up assessment.
Participants without a follow-up assessment were censored at the day of last dose of study treatment.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
OS
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
The mean time, in days, from the date of the first dose of study treatment to the date of death due to any cause.
Participants were censored at the date of the last follow-up assessment.
Participants without a follow-up assessment were censored at the day of last dose of study treatment.
The mean survival time and it's SE were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Number of Participants With PD or Death After a Confirmed CR, CRi, or PR
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Duration of response was defined as the time from the date of the first documented CR, CRi, or PR to the date of disease progression or death.
CR, CRi, PR, and PD as previously defined.
Participants with no documented PD after CR, CRi, or PR were censored at the last date at which they were known to have had CR, CRi, or PR, respectively.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Duration of Response
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
The mean time, in days, from the date of first documented CR, CRi or PR to the date disease progression or death.
CR, CRi, PR, and PD as previously defined.
Participants with no documented PD after CR, CRi, or PR were censored at the last date at which they were known to have had CR, CRi, or PR, respectively.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Number of Participants With PD or Death After a Confirmed CR/CRi
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Disease-free survival was defined at the time from the date of first documented CR or CRi to the date of disease progression or death.
CR, CRi, and PD as previously defined.
Participants with no documented PD after CR or CRi were censored on the last date at which they were known to have had CR or CRi.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Disease-Free Survival
Aikaikkuna: Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
The mean time, in days, from the date of first documented CR or CRi to the date of disease progression or death.
CR, CRi, and PD as previously defined.
Participants with no documented PD after CR or CRi were censored on the last date at which they were known to have had CR or CRi.
In both groups, the mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.
|
Screening, Day 1 Courses 1-8 (4-week courses) and Day 1 of Courses 10-35 (4-week courses) for up to 35 months.
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Maanantai 3. marraskuuta 2008
Ensisijainen valmistuminen (Todellinen)
Maanantai 14. tammikuuta 2013
Opintojen valmistuminen (Todellinen)
Maanantai 14. tammikuuta 2013
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Maanantai 18. elokuuta 2008
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 19. elokuuta 2008
Ensimmäinen Lähetetty (Arvio)
Keskiviikko 20. elokuuta 2008
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Tiistai 15. elokuuta 2017
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Torstai 6. heinäkuuta 2017
Viimeksi vahvistettu
Torstai 1. kesäkuuta 2017
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Immuunijärjestelmän sairaudet
- Neoplasmat histologisen tyypin mukaan
- Neoplasmat
- Lymfoproliferatiiviset häiriöt
- Lymfaattiset sairaudet
- Immunoproliferatiiviset häiriöt
- Leukemia, B-solu
- Leukemia
- Leukemia, lymfosyyttinen, krooninen, B-solu
- Leukemia, imusolmukkeet
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Reumaattiset aineet
- Antineoplastiset aineet
- Immunologiset tekijät
- Antineoplastiset aineet, alkyloiva
- Alkylointiaineet
- Antineoplastiset aineet, immunologiset
- Rituksimabi
- Klorambusiili
Muut tutkimustunnusnumerot
- ML21445
- 2008-001612-20
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Lymfosyyttinen leukemia, krooninen
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrytointiRefractory Chronic Graft versus Host Disease (cGVHD)Belgia
-
National Cancer Institute (NCI)ValmisT-solun suuri rakeinen lymfosyyttinen leukemia | Leukemia, T-Cell Large Granular LymphocyticYhdysvallat
-
Stanford UniversityKeskeytettyKeuhkosairaudet | Bronkiektaasi | Interstitiaalinen keuhkosairaus | Sjogrenin syndrooma | Krooninen bronkioliitti | Primaarinen keuhkolymfooma (häiriö) | Kystinen keuhkosairaus | Lymphocytic Interst. PneumoniittiYhdysvallat
Kliiniset tutkimukset rituximab [MabThera/Rituxan]
-
Children's Oncology GroupNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiEBV:hen liittyvä transplantaation jälkeinen lymfoproliferatiivinen häiriö | Monomorfinen transplantaation jälkeinen lymfoproliferatiivinen häiriö | Polymorfinen siirroksen jälkeinen lymfoproliferatiivinen häiriö | Toistuva monomorfinen siirroksen jälkeinen lymfoproliferatiivinen häiriö | Toistuva... ja muut ehdotYhdysvallat
-
M.D. Anderson Cancer CenterRekrytointiTulenkestävä primaarinen välikarsina (kateenkorva) suuri B-solulymfooma | Richterin oireyhtymä | Tulenkestävä vaippasolulymfooma | Tulenkestävä aggressiivinen B-soluinen non-Hodgkin-lymfooma | Tulenkestävä korkea-asteinen B-solulymfooma | Refractory transformoitu follikulaarinen lymfooma diffuusiksi... ja muut ehdotYhdysvallat
-
M.D. Anderson Cancer CenterAktiivinen, ei rekrytointiVaippasolulymfoomaYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiKrooninen lymfosyyttinen leukemia / pieni lymfosyyttinen lymfoomaYhdysvallat
-
University of WashingtonNational Cancer Institute (NCI)LopetettuToistuva marginaalialueen lymfooma | Waldenströmin makroglobulinemia | Marginaalialueen lymfooma | Refractory marginaalivyöhykkeen lymfooma | Toistuva Waldenströmin makroglobulinemia | Tulenkestävä Waldenströmin makroglobulinemiaYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiAnn Arborin vaiheen I asteen 1 follikulaarinen lymfooma | Ann Arborin vaiheen I asteen 2 follikulaarinen lymfooma | Ann Arborin vaiheen II asteen 1 follikulaarinen lymfooma | Ann Arborin vaiheen II asteen 2 follikulaarinen lymfoomaYhdysvallat
-
National Cancer Institute (NCI)ValmisAnn Arborin vaiheen III asteen 1 follikulaarinen lymfooma | Ann Arborin vaiheen III asteen 2 follikulaarinen lymfooma | Ann Arborin vaiheen IV luokan 1 follikulaarinen lymfooma | Ann Arborin vaiheen IV asteen 2 follikulaarinen lymfooma | Ann Arbor Stage II Grade 3 vierekkäinen follikulaarinen lymfooma ja muut ehdotYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiToistuva pieni lymfosyyttinen lymfooma | Prolymfosyyttinen leukemia | Toistuva krooninen lymfosyyttinen leukemiaYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiKarvasoluleukemia | Toistuva karvasoluleukemiaYhdysvallat
-
Mayo ClinicNational Cancer Institute (NCI)ValmisAnn Arborin vaiheen I asteen 1 follikulaarinen lymfooma | Ann Arborin vaiheen I asteen 2 follikulaarinen lymfooma | Ann Arborin vaiheen III asteen 1 follikulaarinen lymfooma | Ann Arborin vaiheen III asteen 2 follikulaarinen lymfooma | Ann Arborin vaiheen IV luokan 1 follikulaarinen lymfooma | Ann... ja muut ehdotYhdysvallat